Senan Suresh, De Ruysscher Dirk
Department of Radiation Oncology, VU University Medical Center, De Boelelaan 1117, Post Box 7057, 1007 MB Amsterdam, The Netherlands.
Crit Rev Oncol Hematol. 2005 Dec;56(3):345-51. doi: 10.1016/j.critrevonc.2005.05.001. Epub 2005 Jun 28.
In the last decade, FDG-PET scans have had a major impact on the treatment of patients with NSCLC. The benefits of staging PET scans are well established, with improved selection of patients for curative radiotherapy or aggressive chemo-radiotherapy. The large body of literature correlating FDG-PET with nodal pathology in NSCLC makes it rational to use PET for designing mediastinal radiation fields. However, suboptimal image-fusion and a low spatial resolution for PET scans, makes use of PET for defining target volumes for primary tumours questionable. Data on the role of PET scans for radiotherapy planning for limited stage small-cell lung cancer is limited, although the incorporation of FDG-PET positive regions would appear to be reasonable.
在过去十年中，氟代脱氧葡萄糖正电子发射断层扫描（FDG-PET）对非小细胞肺癌（NSCLC）患者的治疗产生了重大影响。分期PET扫描的益处已得到充分证实，它能更好地筛选出适合根治性放疗或积极放化疗的患者。大量将FDG-PET与NSCLC淋巴结病理相关联的文献表明，使用PET来设计纵隔放疗野是合理的。然而，PET扫描的图像融合欠佳以及空间分辨率较低，使得利用PET来确定原发性肿瘤的靶区存在疑问。关于PET扫描在局限期小细胞肺癌放疗计划中的作用的数据有限，尽管纳入FDG-PET阳性区域似乎是合理的。
